OJJAARA-200mg (Momelotinib Tablet) 200 mg

OJJAARA-200mg (momelotinib) is a prescription tablet used for certain blood disorders. This 200 mg formulation helps manage symptoms related to bone marrow issues. Always consult a healthcare provider before use. Short-term relief may vary by individual.

Strength

200 mg

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

OJJAARA-200mg (momelotinib) is prescribed to address symptoms of myelofibrosis, a rare bone marrow disorder. It helps reduce fatigue, anemia, and spleen enlargement in adults. Patients often ask, 'what is momelotinib used for' when discussing treatment options. This medication supports blood cell production in affected individuals.

Side Effects

OJJAARA-200mg (momelotinib) may help stabilize blood counts and improve energy levels over time. Some users report reduced spleen discomfort after consistent use. Individual responses can vary, and effects may take several weeks to become noticeable. Always follow a healthcare provider’s guidance.

Precautions & Warnings

Store OJJAARA-200mg tablets at room temperature, away from moisture and direct light. Keep out of reach of children and pets. Do not use if the packaging is damaged or the tablets appear discolored. Report any unusual symptoms to a healthcare professional promptly.

Avoid Interactions

OJJAARA-200mg may interact with certain medications, including strong CYP3A4 inhibitors or inducers. Avoid grapefruit products while taking this tablet. Alcohol and other central nervous system depressants may increase drowsiness. Always inform your doctor about all medications and supplements in use.

References

Frequently Asked Questions

Momelotinib is prescribed to treat symptoms of myelofibrosis, such as anemia and spleen enlargement.

Effects may take several weeks to become noticeable; follow your healthcare provider’s guidance.

It can be taken with or without food, but consistency in timing is recommended.

Common effects may include dizziness, nausea, or fatigue; report persistent issues to a doctor.

Consult a healthcare provider before use; risks and benefits should be evaluated on an individual basis.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.